Zometa

ApprovedSmall molecule

Novartis

Zometa is one of 162 small molecule programs targeting Bone Metastasis. It is currently in Approved.

Indications

Total Trials

Active Trials

161

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone MetastasisActive, not recruiting

Malignant MesotheliomaActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Bone MetastasisPreclinical

Active, not recruiting

Malignant MesotheliomaPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Multiple MyelomaApproved

Active, not recruiting

Small Cell Lung CancerApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zometa

Novartis

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Acupan

YYonsei University

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Vfend

PPrism Pharmaceuticals

Paracetamol

1 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Metastasis2 trials

Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis

Completed·UUniversity of Louisville··NCT00264082·30 enrolled

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

Completed· Novartis logo

Novartis·Phase 4·NCT00035997·261 enrolled

Bone Loss1 trial

Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)

Completed·MMilton S. Hershey Medical Center·Phase 3·NCT00712985·18 enrolled

Angiogenesis1 trial

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Completed·UUniversity of Arkansas·Phase 2·NCT00083382·83 enrolled

Malignant Mesothelioma1 trial

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT01204203·8 enrolled

Breast Cancer1 trial

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT00242203·120 enrolled

5 more indications

Nasopharyngeal Cancer1 trial

To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer

Completed·SSun Yat-sen University·Phase 2·NCT00697619·60 enrolled

Small Cell Lung Cancer1 trial

Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

Completed·SSun Yat-sen University·Phase 4·NCT00762346·156 enrolled

Bone Metastases1 trial

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

Terminated·CCentral European Cooperative Oncology Group·Phase 3·NCT00294437·376 enrolled

Prostate Cancer1 trial

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00582556·44 enrolled

Multiple Myeloma1 trial

Stage I Multiple Myeloma Treatment

Completed·—·Phase 4·NCT00733538·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Zometa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zometa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zometa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Zometa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Metastasis2 trials

Bone Loss1 trial

Angiogenesis1 trial

Malignant Mesothelioma1 trial

Breast Cancer1 trial

Nasopharyngeal Cancer1 trial

Small Cell Lung Cancer1 trial

Bone Metastases1 trial

Prostate Cancer1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News